Cellular and molecular targeting for nanotherapeutics in transplantation tolerance

Clinical Immunology

Volumn 160, Issue 1, 2015, Pages 14-23

  Hlavaty, Kelan A ^a,b   Luo, Xunrong ^b   Shea, Lonnie D ^c   Miller, Stephen D ^d  

^a Northwestern University   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Nanocarrier; Targeting; Tolerance; Transplantation

Indexed keywords

ALLOANTIGEN; ANTIGEN; BIOMATERIAL; LECTIN RECEPTOR; NANOCARRIER; RAPAMYCIN; TACROLIMUS; DRUG CARRIER; IMMUNOSUPPRESSIVE AGENT;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ENGINEERING; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; GRAFT SURVIVAL; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; PROCEDURES;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS; DRUG CARRIERS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; SIROLIMUS; TACROLIMUS; TRANSPLANTATION TOLERANCE;

EID: 84940447835     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.013     Document Type: Review

References (108)

1. Page E.K., Dar W.A., Knechtle S.J. Tolerogenic therapies in transplantation. Front. Immunol. 2012, 3:198.
2. Angaswamy N., Tiriveedhi V., Sarma N.J., Subramanian V., Klein C., Wellen J., et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum. Immunol. 2013, 74:1478-1485.
3. Nanji S.A., Shapiro A.M. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs 2004, 18:315-328.
4. Masri M.A. The mosaic of immunosuppressive drugs. Mol. Immunol. 2003, 39:1073-1077.
5. Lindahl K.F., Wilson D.B. Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J. Exp. Med. 1977, 145:508-522.
6. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 2001, 166:973-981.
7. Simpson E., Scott D., James E., Lombardi G., Cwynarski K., Dazzi F., et al. Minor H antigens: genes and peptides. Eur. J. Immunogenet. 2001, 28:505-513.
8. Felix N.J., Allen P.M. Specificity of T-cell alloreactivity. Nat. Rev. Immunol. 2007, 7:942-953.
9. Shilling R.A., Wilkes D.S. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am. J. Transplant. 2009, 9:1714-1718.
10. Hachem R.R. Lung allograft rejection: diagnosis and management. Curr. Opin. Organ Transplant. 2009, 14:477-482.
11. Game D.S., Lechler R.I. Pathways of allorecognition: implications for transplantation tolerance. Transpl. Immunol. 2002, 10:101-108.
12. Pietra B.A., Wiseman A., Bolwerk A., Rizeq M., Gill R.G. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J. Clin. Invest. 2000, 106:1003-1010.
13. Pilat N., Sayegh M.H., Wekerle T. Costimulatory pathways in transplantation. Semin. Immunol. 2011, 23:293-303.
14. McCarthy D.P., Hunter Z.N., Chackerian B., Shea L.D., Miller S.D. Targeted immunomodulation using antigen-conjugated nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2014, 6:298-315.
15. Kheradmand T., Wang S., Bryant J., Tasch J.J., Lerret N., Pothoven K.L., et al. Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. J. Immunol. 2012, 189:804-812.
16. Kheradmand T., Wang S., Gibly R.F., Zhang X., Holland S., Tasch J., et al. Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions. Biomaterials 2011, 32:4517-4524.
17. Bryant J., Hlavaty K.A., Zhang X., Yap W.T., Zhang L., Shea L.D., et al. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials 2014, 35:8887-8894.
18. Fehres C.M., Unger W.W., Garcia-Vallejo J.J., van Kooyk Y. Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front. Immunol. 2014, 5:149.
19. Tel J., Sittig S.P., Blom R.A., Cruz L.J., Schreibelt G., Figdor C.G., et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 2013, 191:5005-5012.
20. Reynoso E.D., Turley S.J. Unconventional antigen-presenting cells in the induction of peripheral CD8(+) T cell tolerance. J. Leukoc. Biol. 2009, 86:795-801.
21. Ebrahimkhani M.R., Mohar I., Crispe I.N. Cross-presentation of antigen by diverse subsets of murine liver cells. Hepatology 2011, 54:1379-1387.
22. Getts D.R., McCarthy D.P., Miller S.D. Exploiting apoptosis for therapeutic tolerance induction. J. Immunol. 2013, 191:5341-5346.
23. Hirosue S., Vokali E., Raghavan V.R., Rincon-Restrepo M., Lund A.W., Corthesy-Henrioud P., et al. Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells. J. Immunol. 2014, 192:5002-5011.
24. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 2006, 112:26-34.
25. Tiegs G., Lohse A.W. Immune tolerance: what is unique about the liver. J. Autoimmun. 2010, 34:1-6.
26. Sadauskas E., Wallin H., Stoltenberg M., Vogel U., Doering P., Larsen A., et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part. Fibre Toxicol. 2007, 4:10.
27. Ravishankar B., McGaha T.L. O death where is thy sting? Immunologic tolerance to apoptotic self. Cell. Mol. Life Sci. 2013, 70:3571-3589.
28. Kamei T., Callery M.P., Flye M.W. Kupffer cell blockade prevents induction of portal venous tolerance in rat cardiac allograft transplantation. J. Surg. Res. 1990, 48:393-396.
29. You Q., Cheng L., Kedl R.M., Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 2008, 48:978-990.
30. Knolle P.A., Schmitt E., Jin S., Germann T., Duchmann R., Hegenbarth S., et al. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology 1999, 116:1428-1440.
31. Berg M., Wingender G., Djandji D., Hegenbarth S., Momburg F., Hammerling G., et al. Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance. Eur. J. Immunol. 2006, 36:2960-2970.
32. Schurich A., Bottcher J.P., Burgdorf S., Penzler P., Hegenbarth S., Kern M., et al. Distinct kinetics and dynamics of cross-presentation in liver sinusoidal endothelial cells compared to dendritic cells. Hepatology 2009, 50:909-919.
33. von Oppen N., Schurich A., Hegenbarth S., Stabenow D., Tolba R., Weiskirchen R., et al. Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization. Hepatology 2009, 49:1664-1672.
34. Schurich A., Berg M., Stabenow D., Bottcher J., Kern M., Schild H.J., et al. Dynamic regulation of CD8 T cell tolerance induction by liver sinusoidal endothelial cells. J. Immunol. 2010, 184:4107-4114.
35. Onoe T., Ohdan H., Tokita D., Shishida M., Tanaka Y., Hara H., et al. Liver sinusoidal endothelial cells tolerize T cells across MHC barriers in mice. J. Immunol. 2005, 175:139-146.
36. Tokita D., Ohdan H., Onoe T., Hara H., Tanaka Y., Asahara T. Liver sinusoidal endothelial cells contribute to alloreactive T-cell tolerance induced by portal venous injection of donor splenocytes. Transpl. Int. 2005, 18:237-245.
37. Akhter A., Hayashi Y., Sakurai Y., Ohga N., Hida K., Harashima H. Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells. Int. J. Pharm. 2014, 475:227-237.
38. McGaha T.L., Chen Y., Ravishankar B., van Rooijen N., Karlsson M.C. Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood 2011, 117:5403-5412.
39. Miyake Y., Asano K., Kaise H., Uemura M., Nakayama M., Tanaka M. Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. J. Clin. Invest. 2007, 117:2268-2278.
40. Getts D.R., Turley D.M., Smith C.E., Harp C.T., McCarthy D., Feeney E.M., et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 2011, 187:2405-2417.
41. Prasad S., Kohm A.P., McMahon J.S., Luo X., Miller S.D. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J. Autoimmun. 2012, 39:347-353.
42. Smarr C.B., Hsu C.L., Byrne A.J., Miller S.D., Bryce P.J. Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J. Immunol. 2011, 187:5090-5098.
43. Luo X., Pothoven K.L., McCarthy D., DeGutes M., Martin A., Getts D.R., et al. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14527-14532.
44. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
45. den Haan J.M., Lehar S.M., Bevan M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000, 192:1685-1696.
46. Iyoda T., Shimoyama S., Liu K., Omatsu Y., Akiyama Y., Maeda Y., et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002, 195:1289-1302.
47. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25:1159-1164.
48. Ito T., Hanabuchi S., Wang Y.H., Park W.R., Arima K., Bover L., et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
49. Yoneyama H., Narumi S., Zhang Y., Murai M., Baggiolini M., Lanzavecchia A., et al. Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J. Exp. Med. 2002, 195:1257-1266.
50. Chappell C.P., Giltiay N.V., Draves K.E., Chen C., Hayden-Ledbetter M.S., Shlomchik M.J., et al. Targeting antigens through blood dendritic cell antigen 2 on plasmacytoid dendritic cells promotes immunologic tolerance. J. Immunol. 2014, 192:5789-5801.
51. Geijtenbeek T.B., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 2009, 9:465-479.
52. Azad A.K., Rajaram M.V., Schlesinger L.S. Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics. J. Cytol. Mol. Biol. 2014, 1.
53. Kawakami S., Sato A., Nishikawa M., Yamashita F., Hashida M. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther. 2000, 7:292-299.
54. D'Addio S.M., Baldassano S., Shi L., Cheung L., Adamson D.H., Bruzek M., et al. Optimization of cell receptor-specific targeting through multivalent surface decoration of polymeric nanocarriers. J. Control. Release 2013, 168:41-49.
55. White K.L., Rades T., Furneaux R.H., Tyler P.C., Hook S. Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cells. J. Pharm. Pharmacol. 2006, 58:729-737.
56. Kel J., Oldenampsen J., Luca M., Drijfhout J.W., Koning F., Nagelkerken L. Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis. Am. J. Pathol. 2007, 170:272-280.
57. Mahnke K., Guo M., Lee S., Sepulveda H., Swain S.L., Nussenzweig M., et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 2000, 151:673-684.
58. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 2002, 196:1627-1638.
59. Witmer-Pack M.D., Swiggard W.J., Mirza A., Inaba K., Steinman R.M. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell. Immunol. 1995, 163:157-162.
60. Cruz L.J., Rosalia R.A., Kleinovink J.W., Rueda F., Lowik C.W., Ossendorp F. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8 T cell response: a comparative study. J. Control. Release 2014, 192C:209-218.
61. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001, 194:769-779.
62. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
63. Carter R.W., Thompson C., Reid D.M., Wong S.Y., Tough D.F. Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J. Immunol. 2006, 177:2276-2284.
64. Taylor P.R., Brown G.D., Reid D.M., Willment J.A., Martinez-Pomares L., Gordon S., et al. The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol. 2002, 169:3876-3882.
65. Rogers N.C., Slack E.C., Edwards A.D., Nolte M.A., Schulz O., Schweighoffer E., et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 2005, 22:507-517.
66. Dillon S., Agrawal S., Banerjee K., Letterio J., Denning T.L., Oswald-Richter K., et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 2006, 116:916-928.
67. Sancho D., Joffre O.P., Keller A.M., Rogers N.C., Martinez D., Hernanz-Falcon P., et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009, 458:899-903.
68. Schreibelt G., Klinkenberg L.J., Cruz L.J., Tacken P.J., Tel J., Kreutz M., et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-) presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012, 119:2284-2292.
69. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010, 207:1247-1260.
70. Poulin L.F., Salio M., Griessinger E., Anjos-Afonso F., Craciun L., Chen J.L., et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010, 207:1261-1271.
71. Joffre O.P., Sancho D., Zelenay S., Keller A.M., Reis e Sousa C. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur. J. Immunol. 2010, 40:1255-1265.
72. Barker R.N., Erwig L., Pearce W.P., Devine A., Rees A.J. Differential effects of necrotic or apoptotic cell uptake on antigen presentation by macrophages. Pathobiology 1999, 67:302-305.
73. Viorritto I.C., Nikolov N.P., Siegel R.M. Autoimmunity versus tolerance: can dying cells tip the balance?. Clin. Immunol. 2007, 122:125-134.
74. Wermeling F., Chen Y., Pikkarainen T., Scheynius A., Winqvist O., Izui S., et al. Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J. Exp. Med. 2007, 204:2259-2265.
75. Getts D.R., Martin A.J., McCarthy D.P., Terry R.L., Hunter Z.N., Yap W.T., et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 2012, 30:1217-1224.
76. Arredouani M., Yang Z., Ning Y., Qin G., Soininen R., Tryggvason K., et al. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J. Exp. Med. 2004, 200:267-272.
77. Guo C., Yi H., Yu X., Hu F., Zuo D., Subjeck J.R., et al. Absence of scavenger receptor A promotes dendritic cell-mediated cross-presentation of cell-associated antigen and antitumor immune response. Immunol. Cell Biol. 2012, 90:101-108.
78. Yi H., Yu X., Gao P., Wang Y., Baek S.H., Chen X., et al. Pattern recognition scavenger receptor SRA/CD204 down-regulates Toll-like receptor 4 signaling-dependent CD8 T-cell activation. Blood 2009, 113:5819-5828.
79. Platt N., Suzuki H., Kodama T., Gordon S. Apoptotic thymocyte clearance in scavenger receptor class A-deficient mice is apparently normal. J. Immunol. 2000, 164:4861-4867.
80. Li D., Romain G., Flamar A.L., Duluc D., Dullaers M., Li X.H., et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J. Exp. Med. 2012, 209:109-121.
81. Shan J., Feng L., Li Y., Sun G., Chen X., Chen P. The effects of rapamycin on regulatory T cells: its potential time-dependent role in inducing transplant tolerance. Immunol. Lett. 2014, 162:74-86.
82. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
83. Klintmalm G.B., Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J. Transplant. 2014, 2014:845438.
84. Scheffert J.L., Raza K. Immunosuppression in lung transplantation. J. Thorac. Dis. 2014, 6:1039-1053.
85. Blagosklonny M.V. Immunosuppressants in cancer prevention and therapy. Oncoimmunology 2013, 2:e26961.
86. Martinet W., De Loof H., De Meyer G.R. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 2014, 233:601-607.
87. Bertagnolli M.M., Yang L., Herrmann S.H., Kirkman R.L. Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes. Transplantation 1994, 58:1091-1096.
88. Aagaard-Tillery K.M., Jelinek D.F. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell. Immunol. 1994, 156:493-507.
89. Haddadi A., Elamanchili P., Lavasanifar A., Das S., Shapiro J., Samuel J. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J. Biomed. Mater. Res. A 2008, 84:885-898.
90. Napoli K.L., Wang M.E., Stepkowski S.M., Kahan B.D. Distribution of sirolimus in rat tissue. Clin. Biochem. 1997, 30:135-142.
91. Zou W., Cao G., Xi Y., Zhang N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv. 2009, 16:15-23.
92. Jhunjhunwala S., Balmert S.C., Raimondi G., Dons E., Nichols E.E., Thomson A.W., et al. Controlled release formulations of IL-2, TGF-beta1 and rapamycin for the induction of regulatory T cells. J. Control. Release 2012, 159:78-84.
93. Das S., Haddadi A., Veniamin S., Samuel J. Delivery of rapamycin-loaded nanoparticle down regulates ICAM-1 expression and maintains an immunosuppressive profile in human CD34+ progenitor-derived dendritic cells. J. Biomed. Mater. Res. A 2008, 85:983-992.
94. Gu Y., Hu Y., Hu K., Liao W., Zheng F., Yu X., et al. Rapamycin together with TGF-beta1, IL-2 and IL-15 induces the generation of functional regulatory gammadeltaT cells from human peripheral blood mononuclear cells. J. Immunol. Methods 2014, 402:82-87.
95. Maldonado R.A., LaMothe R.A., Ferrari J.D., Zhang A.H., Rossi R.J., Kolte P.N., et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E156-E165.
96. Bisht S., Feldmann G., Koorstra J.B., Mullendore M., Alvarez H., Karikari C., et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol. Cancer Ther. 2008, 7:3878-3888.
97. Dane K.Y., Nembrini C., Tomei A.A., Eby J.K., O'Neil C.P., Velluto D., et al. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. J. Control. Release 2011, 156:154-160.
98. Woo H.N., Chung H.K., Ju E.J., Jung J., Kang H.W., Lee S.W., et al. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int. J. Nanomedicine 2012, 7:2197-2208.
99. Chen Y.C., Lo C.L., Lin Y.F., Hsiue G.H. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials 2013, 34:1115-1127.
100. Shin S.B., Cho H.Y., Kim D.D., Choi H.G., Lee Y.B. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur. J. Pharm. Biopharm. 2010, 74:164-171.
101. Wong S.H. Therapeutic drug monitoring for immunosuppressants. Clin. Chim. Acta 2001, 313:241-253.
102. Brazelton T.R., Morris R.E. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr. Opin. Immunol. 1996, 8:710-720.
103. Xu W., Ling P., Zhang T. Toward immunosuppressive effects on liver transplantation in rat model: tacrolimus loaded poly(ethylene glycol)-poly(D, L-lactide) nanoparticle with longer survival time. Int. J. Pharm. 2014, 460:173-180.
104. Saunders R.N., Metcalfe M.S., Nicholson M.L. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001, 59:3-16.
105. Chen H., Qi S., Xu D., Vu D.M., Fitzsimmons W.E., Bekersky I., et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant. Proc. 1998, 30:1039-1041.
106. Fitzhugh C.D., Weitzel R.P., Hsieh M.M., Phang O.A., Madison C., Luznik L., et al. Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplant. 2013, 48:1335-1341.
107. Stepkowski S.M., Kahan B.D. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant. Proc. 1991, 23:3262-3264.
108. Dai W., Yang F., Ma L., Fan Y., He B., He Q., et al. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin alpha3 in triple-negative breast cancer. Biomaterials 2014, 35:5347-5358.